ArticleBMC pulmonary medicine2026
Reactive thrombocytosis in hospitalized pneumonia reflects intense inflammation and confers context-dependent mortality risk.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBeyond hemostasis, platelets’ immune and inflammatory role is recognized and thrombocytosis is generally regarded as a marker of the inflammatory response. However, the immune functions of platelets remain beneath the surface, and previous studies have reported conflicting findings regarding the significance of thrombocytosis in infection-related diseases. Can reactive thrombocytosis be viewed as a “higher-is-worse or higher-is-better” predictor of clinical outcome?
methodsWe analyzed 2754 patients discharged from the respiratory and infectious-disease wards between 1 January 2021 and 11 June 2025, and patients from the MIMIC-IV 3.1 database were used as validation cohorts, grouped by peak platelet counts (< 90, ≥ 400, 90–399 × 10⁹/L). Cox regression and multivariate logistic regression were performed to analyze the relationship between platelet count and in-hospital mortality. Multivariate linear regression was used to analyze the relationship between platelet count and length of hospital stay (LOS).
resultsPatients with reactive thrombocytosis had longer hospital stays (13 vs. 10 days; p < 0.001) and higher inflammatory markers than those with normal platelet counts CRP (90.2 vs. 28.6 mg/L; p < 0.001), PCT (0.195 vs. 0.092 ng/mL; p < 0.001), WBC (12.6 vs. 8.4 × 10⁹/L; p < 0.001). Despite these differences, mortality (3.4% vs. 4.4%) did not differ, nor did the rates of bloodstream, fungal, or polymicrobial infections. Clustering analyses confirmed comparable overall microbial spectra between the two groups. The impact of thrombocytosis on mortality (HR, 0.52; 95% CI, 0.27–0.99; p = 0.047) is context-dependent: it trended toward higher mortality in non-septic patients (OR, 1.42; 95% CI, 0.64–2.86, p = 0.357) but toward lower mortality in those with sepsis (OR, 0.33; 95% CI, 0.05–1.51, p = 0.18). The same opposing pattern and the interaction of sepsis and thrombocytosis re-emerged (OR, 1.70; 95% CI, 0.95–2.92, p = 0.063 vs. OR, 0.58; 95% CI, 0.34–0.96, p = 0.04) in MIMIC-IV data. Thrombocytopenia is an independent risk factor for mortality (HR, 2.08; 95% CI, 1.48–2.93; p < 0.001) and has good combined predictive ability.
conclusionsThrombocytosis trended toward higher mortality in non-septic patients yet toward lower mortality in those with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.